Brexanolone, a GABAA Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review - PubMed (original) (raw)

Review

doi: 10.3389/fpsyt.2021.699740. eCollection 2021.

Amira S Odisho 1, Kendall Lewis 2, Amir Kaskas 2, Grace Hunt 2, Elyse M Cornett 3, Alan D Kaye 3, Adam Kaye 4, John Morgan 5, P Scott Barrilleaux 5, David Lewis 5, Omar Viswanath 4 6 7 8, Ivan Urits 3 9

Affiliations

Review

Brexanolone, a GABAA Modulator, in the Treatment of Postpartum Depression in Adults: A Comprehensive Review

Amber N Edinoff et al. Front Psychiatry. 2021.

Abstract

Postpartum depression (PPD) is one of the three major categories on the spectrum of postpartum psychiatric syndromes. Postpartum psychiatric syndromes are classified as either postpartum blues, postpartum depression, or postpartum psychosis. Postpartum depression is important to recognize clinically because of the effect it can have on the mother-child bond. The neurosteroid allopregnanolone, a progesterone derivative, is important for its role in positively modulating GABAA receptors. GABA-mediated signaling has been previously implicated in major depressive disorder. Allopregnanolone-mediated signaling has been identified as an important therapeutic target. Treatment with an allopregnanolone-analog, brexanolone, has been shown to improve depression scores in trials for the treatment of PPD. Brexanolone is a positive allosteric modulator of GABAA and is the first drug approved by the FDA to treat postpartum depression. Brexanolone enhances the inhibitory effects of GABAA, restores dysfunctional GABAA transmembrane channels, and mimics a naturally produced progesterone metabolite that fluctuates during pregnancy and postpartum. One open-label study and two phase two studies have some significant reduction in HAM-D scores after treatment and that the effect was still there 30 days post-treatment. Per the data reported, intravenous infusion of brexanolone could be efficacious and safe for the treatment of women suffering from postpartum depression.

Keywords: GABA; allopregnanolone; brexanolone; postpartum depression; postpartum mood disorder.

Copyright © 2021 Edinoff, Odisho, Lewis, Kaskas, Hunt, Cornett, Kaye, Kaye, Morgan, Barrilleaux, Lewis, Viswanath and Urits.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1

Figure 1

Chemical structure of brexanolone.

References

    1. Sriraman NK, Pham DQ, Kumar R. Postpartum depression: What do pediatricians need to know? Pediatr Rev. (2017) 38:541–51. 10.1542/pir.2015-0133 - DOI - PubMed
    1. Earls MF, Siegel BS, Dobbins MI, Garner AS, McGuinn L, Pascoe J, et al. Clinical report—incorporating recognition and management of perinatal and postpartum depression into pediatric practice. Pediatrics. (2010) 126:1032–9. 10.1542/peds.2010-2348 - DOI - PubMed
    1. Association AP. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Press; (2000).
    1. Pearlstein T, Howard M, Salisbury A, Zlotnick C. Postpartum depression. Am J Obstetr Gynecol. (2009) 200:357–64. 10.1016/j.ajog.2008.11.033 - DOI - PMC - PubMed
    1. Oppo A, Mauri M, Ramacciotti D, Camilleri V, Banti S, Borri C, et al. Risk factors for postpartum depression: The role of the Postpartum Depression Predictors Inventory-Revised (PDPI-R) : Rlts from the Perinatal Depression-Research Sc&reening Unit (PNDReScU) study. Arch Women's Ment Health. (2009) 12:239–49. 10.1007/s00737-009-0071-8 - DOI - PubMed

Publication types

LinkOut - more resources